Telix Pharmaceuticals shares (ASX: TLX) have been upgraded to Outperform from Sector Perform at RBC Capital, with the firm citing valuation as the primary catalyst after shares plunged 56% over the past twelve months, offering what the broker describes as a “compelling risk/reward profile” for long-term investors.
The Telix share price has made 52 week lows of A$10.88 earlier this month, and whilst currently hovering around A$11.28, TLX remains close to lows, with the 52 week high of A$31.97 a long way away.
RBC make the upgrade despite maintaining its A$17 price target unchanged, suggesting a potential upside of ~50% from here. The dramatic selloff has been driven by concerns surrounding regulatory setbacks and expectations of flat earnings growth through FY2027, creating a disconnect between market sentiment and fundamental business performance that RBC now views as overdone.
The upgrade comes as Telix navigates a complex period marked by both significant achievements and notable challenges. In February 2025, the company reported robust full-year 2024 results with revenue surging 56% to A$783.2 million, primarily driven by strong commercial uptake of Illuccix, its flagship prostate cancer diagnostic imaging agent. Management provided FY2025 revenue guidance of A$1.18 billion to A$1.23 billion, representing continued strong growth momentum despite the market’s pessimistic reaction.
However, regulatory headwinds have weighed heavily on investor confidence. In August 2025, the U.S. Food and Drug Administration identified deficiencies in the Chemistry, Manufacturing, and Controls package for TLX250-CDx (Zircaix), the company’s renal cell carcinoma imaging candidate, delaying the Biologics License Application process. This setback triggered downgrades from several brokers and intensified concerns about the company’s ability to expand its commercial portfolio beyond Illuccix in the near term.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
RBC’s analysis acknowledges these challenges, forecasting flat earnings and free cash flow between FY2025 and FY2027 as Telix significantly increases research and development investments to advance its extensive pipeline. The firm notes that while this investment phase will pressure near-term profitability metrics, it positions the company for longer-term growth across multiple oncology indications. The broker’s Outperform rating reflects confidence that current valuation levels more than compensate for execution risks.
Adding to the bullish thesis, HC Wainwright reiterated its Buy rating on December 22, 2025, with a price target of $20.00 on the NASDAQ-listed shares, implying potential upside of approximately 156% from recent levels. The firm highlighted Telix’s successful commercialisation of two prostate cancer diagnostic assets and the breadth of its development pipeline as key strengths that markets have underappreciated during the recent downturn.
Bull Case:
- Revenue guidance of up to A$1.23 billion shows strong commercial momentum
- 56% share price decline creates attractive entry point relative to fundamentals
- Expanded manufacturing capabilities position company for multi-product commercial scale
- Deep pipeline across oncology creates multiple value creation pathways
- Two analysts rate stock Outperform or Buy with significant upside targets
Bear Case:
- FDA deficiencies delay TLX250-CDx approval, limiting near-term product expansion opportunities
- Flat earnings and cash flow forecast through FY2027 pressures valuation
- Heavy R&D investment increases execution risk across multiple development programs
- Stock trading near 52-week lows suggests continued downward technical pressure
- Regulatory uncertainty remains elevated following recent FDA feedback on submissions
Now bulls are faced with whether the 56% decline has created a genuine buying opportunity in a fundamentally strong business facing temporary headwinds, or whether regulatory uncertainties and the extended path to profitability growth justify continued caution. RBC’s upgrade suggests the former, yet there could be further twists in this tale yet.
